Can-Fite to Harness Artificial Intelligence to Develop Novel Anti-Cancer Drugs
Portfolio Pulse from Charles Gross
Can-Fite BioPharma Ltd. (NYSE:CANF) has entered into an agreement with Collaborations Pharmaceuticals, Inc. (CPI) to develop anti-cancer drugs using artificial intelligence (AI) and machine learning (ML) techniques. The project aims to develop a next-generation A3 adenosine receptor drug agonists, reducing the development time and cost of bringing such drugs to market.
October 26, 2023 | 11:09 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Can-Fite BioPharma's partnership with CPI to develop AI and ML-based anti-cancer drugs could potentially reduce development time and costs, potentially boosting the company's profitability.
The partnership with CPI allows Can-Fite BioPharma to leverage AI and ML technologies in drug development, which could significantly reduce the time and cost of bringing new drugs to market. This could potentially lead to increased profitability for the company, positively impacting its stock price.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 100